CJC-1295 without DAC 10mg

CJC-1295 without DAC 10mg is a high-purity, research-grade peptide classified as a short-acting Growth Hormone Releasing Hormone (GHRH) analog, also known as Mod GRF 1-29. Developed exclusively for in-vitro and preclinical research, it is engineered to support advanced investigations into pulsatile growth hormone (GH) secretion, endocrine signaling, and somatotropic pathway dynamics.

With its increased 10mg quantity, this format is ideal for extended research protocols and scalable experimental designs. Its short-acting profile and enhanced stability make it a preferred compound for researchers requiring precise control over hormone release timing.

Overview

CJC-1295 without DAC 10mg is widely recognized for its ability to closely mimic the natural activity of GHRH while offering improved resistance to enzymatic degradation. Unlike DAC-modified variants, this peptide provides a shorter duration of action, enabling more accurate modeling of physiological GH pulse patterns.

Researchers studying endocrine function, GH axis regulation, and peptide synergy frequently rely on this compound in both standalone and combination studies. Its predictable pharmacokinetic behavior supports highly controlled and repeatable research outcomes.

Chemical Profile

Peptide Type: GHRH analog (Mod GRF 1-29)
Compound: CJC-1295 without DAC
Target Receptor: GHRH receptors
Primary Function: Pulsatile growth hormone release research

Mechanism of Action

CJC-1295 without DAC 10mg functions by binding to GHRH receptors located in the pituitary gland, activating intracellular signaling pathways responsible for growth hormone synthesis and release.

Due to its short half-life, it supports transient and controlled GH spikes, closely reflecting natural secretion rhythms. Its structural modifications enhance stability, allowing for reliable receptor interaction while avoiding prolonged stimulation associated with longer-acting analogs.

Research and Experimental Applications

CJC-1295 without DAC 10mg is widely utilized in laboratory studies focused on:

• Pulsatile growth hormone secretion analysis
• GH axis regulation and endocrine signaling
• IGF-1 production and downstream pathway research
• Combination peptide studies with GHS compounds
• Somatotropic system investigation
• Time-dependent hormone response experiments

Its short-acting nature makes it especially valuable for research requiring precise timing and repeated stimulation cycles.

Why Researchers Choose CJC-1295 without DAC 10mg

• Higher 10mg quantity for extended and scalable research use
• Short half-life for precise, time-controlled GH studies
• Enhanced stability compared to native GHRH(1-29)
• Ideal for pulsatile secretion and timing-based protocols
• High purity (≥99%) for consistent, reproducible results
• Compatible with combination peptide research models

Additional Research Insights

In controlled research environments, CJC-1295 without DAC has demonstrated reliable activation of growth hormone pathways with a short activity window. This makes it particularly useful for studying natural hormone rhythms and intermittent secretion patterns.

Ongoing research continues to explore its role in combination protocols and endocrine timing studies, where controlled GH release is essential. Its ability to model physiological secretion patterns reinforces its value in advanced peptide research.

Product Specifications

Product Name: CJC-1295 without DAC
Quantity: 10mg per vial
Form: Lyophilized powder
Purity: ≥99%

Storage Instructions

Store CJC-1295 without DAC 10mg in a cool, dry place away from direct light. Refrigeration is recommended to maintain stability, especially after reconstitution in research settings.

Important Notice

CJC-1295 without DAC 10mg is intended strictly for research and laboratory use only. It is not approved for human consumption, veterinary use, or therapeutic applications. All handling must be performed by qualified professionals in compliance with applicable laws and regulations.